Where IDEXX Laboratories Stands With Analysts
Portfolio Pulse from Benzinga Insights
IDEXX Laboratories (NASDAQ:IDXX) has received mixed analyst ratings over the past three months, with a shift towards more bullish sentiment in the last 30 days. Analysts have raised their 12-month price targets, indicating an average target of $615.0, an 8.21% increase from the previous average. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, but it faces challenges with a high debt-to-equity ratio. IDXX develops and distributes diagnostic products for pets and livestock, with significant revenue from outside the U.S.
February 06, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEXX Laboratories has seen a positive shift in analyst sentiment with raised price targets, indicating confidence in its future performance despite a high debt-to-equity ratio.
The increase in the average price target by analysts suggests a bullish outlook for IDXX's stock in the short term. The company's strong financial indicators such as revenue growth, net margin, ROE, and ROA support this positive sentiment. However, the high debt-to-equity ratio is a concern that investors should monitor. The recent analyst upgrades and raised price targets are likely to positively impact IDXX's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100